"ApToll is an immune modulator to treat ischaemic stroke in the acute phase. We have suc... 10/10/2024 Healthcare Innovative drugs David Segarra, an aptamer technology entrepreneur, co-founded aptaTargets in 2014 and has led the company to bring... Partners - GENESIS Biomed
Fecundis secures $2.4 million in seed funding 08/10/2024 Healthcare Access to innovation Personalized medicine This funding will allow the company -based in the Barcelona Science Parkspeed up the path to market of their first... Partners - Parc Científic de Barcelona
AEMPS approves Peaches clinical trial with selective secretomes to treat COVID-19-associat... 08/10/2024 Healthcare Innovative drugs Personalized medicine Peaches starts its phase I-II pilot trial to obtain an advanced biologic drug that will help combat cytokine storm, a... Partners - PEACHES BIOTECH S.L.
DMPK and Bioanalytical Strategies for the Successful Development of Antibody-Drug Conjugat... Del 29/10/2024 16:00 to 29/10/2024 Healthcare Drug discovery International
Fundación Teófilo Hernando, CRO in Spain of a pivotal clinical study with the first medica... 03/10/2024 Healthcare Access to innovation Personalized medicine The international study involves the Complexo Hospitalario Universitario de A Coruña in Spain and two other sites in... Partners - Fundación Teófilo Hernando (FTH)
Alira Health Releases 2024 Biologics and Advanced Therapies CDMO Market Report Amid Contin... 02/10/2024 Healthcare Drug discovery Advanced therapies International Despite market contraction in 2023, strategic interest in biologics and advanced therapies remains robust, with a... Partners
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase I... 01/10/2024 Healthcare Innovative drugs Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2. Partners - Oryzon Genomics
Asabys Announces the Closing of €180M Oversubscribed Sabadell Asabys II Fund 01/10/2024 Healthcare Financing Digitalization Similar to Sabadell Asabys Fund I, the Fund II portfolio will include companies within the fields of biopharma, medtech... Partners - Asabys Partners
BCN HEALTH publishes a study on productivity losses due to Hodgkin's and non-Hodgkin's lym... 27/09/2024 Healthcare BCN HEALTH has published the study ‘Burden of Hodgkin and non-Hodgkin lymphoma in Spain over a 10-year period... Partners - BCN Health
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-... 25/09/2024 Healthcare Innovative drugs Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain... Partners - THERIVA BIOLOGICS S.L.
